Sign in
BNTX Stock Price, Chart, Stats & News
BioNTech SE
Save
22.81B
Market cap
–
Current P/E
7.04x
Forward P/E
BNTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 77.68% |
Operating margin | -45.88% |
Pretax margin | -36.65% |
Net margin | -39.60% |
Effective tax rate | -8.06% |
ROA | -5.16% |
ROE | -6.03% |
D/E | 0.01x |
Interest coverage ratio | -80.27x |
BNTX valuation
P/E | – |
P/S | 6.52x |
P/B | 0.95x |
P/CF | 39.21x |
P/FCF | 67.46x |
P/OCF | 39.21x |
PEG | 0.19x |
EV multiple | -41.05x |
About
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer.
Similar securities
Based on sector and market capitalization
Report issue